<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538771</url>
  </required_header>
  <id_info>
    <org_study_id>DAMI</org_study_id>
    <nct_id>NCT01538771</nct_id>
  </id_info>
  <brief_title>Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling</brief_title>
  <official_title>The Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion: Gauging Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction (ICEBERG).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized and open label trial

      Hypothesis

        -  Infusion of intracoronary darbepoetin-alpha at the time of reperfusion may reduce
           infarct size and post-infarct pathologic left ventricular remodeling in patients with
           ST-segment elevation myocardial infarction.

      Methods

        -  Randomization into control group or treatment group

        -  Treatment group : Darbepoetin-alpha 300ug intracoronary bolus infusion via over-the-wire
           balloon system simultaneously with first balloon inflation and conventional treatment

        -  Control group : conventional treatment

      Endpoints

        -  peak CK-MB &amp; troponin levels : baseline,6h,12hr,18hr, 24hr, 36hr and 48hr

        -  MRI at baseline : infarct size, area at risk and salvaged myocardium

        -  MRI at 4 months : prevalence of pathologic left ventricle remodeling (definition:
           increase of end-diastolic volume index &gt; 20% compared to baseline)

        -  safety endpoint : cardiac death, nonfatal myocardial infarction, stent thrombosis,
           ischemic stroke, hospital readmission with heart failure or ischemic symptom, bleeding
           and urgent target lesion revascularization
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Eligibility Criteria]

      1. Patients, regardless of gender, at the age from 18 to 80 years were eligible if they had
      within 12 hours of onset of ST-segment myocardial infarction that was decided to treat with
      primary percutaneous coronary intervention.

      [Exclusion criteria]

        1. Uncontrolled congestive heart failure (Killip classes II and III, or cardiogenic shock)

        2. History of malignancy

        3. Serious hematological disease

        4. Current infectious disease requiring antibiotic therapy

        5. Baseline creatinine level &gt; 2.0 mg/dL or dependence on dialysis

        6. Known hypersensitivity to or contraindication for heparin, aspirin, clopidogrel,
           sirolimus, everolimus, contrast medium and darbepoetin-α

      [Primary endpoint] Myocardial infarct size, estimated by measurement of peak levels of
      cardiac biomarker (CK-MB and troponin-I of the patients was followed for 48 hours at every 6
      hours)

      [Secondary end points]

        1. The infarct size, measured as the area of delayed enhancement seen with cardiac magnetic
           resonance (CMR) imaging on average four days after ST-segment elevation myocardial
           infarction (baseline)

        2. The proportion of area at risk (AAR) and salvaged myocardium, calculated by formula;
           [AAR - Infarct size] / AAR X 100 (%)

        3. The change of left ventricular ejection fraction (LVEF), LV end-diastolic volume
           (LVEDV), and LV end-systolic volume (LVESV) assessed by CMR between four days and four
           months

        4. LV remodeling index [(LVEDV at four months - baseline LVEDV) / baseline LVEDV X 100%]
           and the incidence of pathologic LV remodeling (LV remodeling index &gt; 20%);

      [Safety endpoints] The incidence of composites of the cardiovascular endpoints (cardiac
      death, nonfatal myocardial infarction, stent thrombosis, ischemic stroke, hospital
      readmission with heart failure or ischemic symptoms, bleeding and urgent target lesion
      revascularization) assessed at four months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak CK-MB/ Troponin-I levels</measure>
    <time_frame>baseline, 6, 12,18,24,36,48hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size, area at risk and proportion of salvaged myocardium</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 days</time_frame>
    <description>Assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic left ventricle remodeling assessed by cardiac MRI</measure>
    <time_frame>4 months</time_frame>
    <description>Definition : Increase of end-diastolic volume of left ventricle &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular ejection fraction, LV end-diastolic volume , and LV end-systolic volume assessed by cardiac MRI</measure>
    <time_frame>Between four days and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composites of cardiovascular endpoints</measure>
    <time_frame>4 Months</time_frame>
    <description>ccardiac death, nonfatal myocardial infarction, stent thrombosis, ischemic stroke, hospital readmission with heart failure or ischemic symptoms, bleeding and target lesion revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received same volume of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning &amp; conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment</description>
    <arm_group_label>Darbepoetin group</arm_group_label>
    <other_name>Nesp PFS Prefilled Syringe (Jeilkirin Pharm. Korea)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Saline</intervention_name>
    <description>Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>0.9% normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-elevation myocardial infarction (MI) within 12 hours of onset

          -  Suitable coronary anatomy for PCI

          -  Age &lt; 80 yrs

        Exclusion Criteria:

          -  Uncontrolled congestive heart failure (Killip classes II and III, or cardiogenic
             shock)

          -  History of malignancy

          -  Serious hematological disease

          -  Current infectious disease requiring antibiotic therapy

          -  Baseline creatinine level &gt; 2.0 mg/dL or dependence on dialysis

          -  Known hypersensitivity to or contraindication for heparin, aspirin, clopidogrel,
             sirolimus, everolimus, contrast medium and darbepoetin-α
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ju Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Myocardial reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

